It was reported that a prognostic signature consisting of immune-related long non-coding RNAs, such as CTLA-4, PDCD1, and so on, correspondingly predicted risk of cervical cancer and responded to cervical cancer patients’ immunotherapy of mitomycin C and chemotherapeutics of axitinib and docetaxel [13]. This evidence concerns the gene CTLA4 and cervical cancer.